Cardiac Assist System Protects Against Cardiogenic Shock
By HospiMedica International staff writers Posted on 22 Dec 2015 |
Image: The XENIOS i-cor Synchronized Cardiac Assist System (Photo courtesy of XENIOS).
An innovative synchronized cardiac assist system overlays an artificial heartbeat over a natural weakened heartbeat, thus providing a direct cardiac-assist modality.
The XENIOS i-cor synchronized cardiac assist system uses a miniaturized pump to provide physiological beat-to-beat cardiac assist and concomitant synchronized electrocardiogram (ECG)-triggered pulses that are superimposed over the patient’s weakened heartbeats. The combined myocardial protection and organ perfusion assist the weakened heart to significantly improve coronary blood flow and limit afterload, when compared with conventional methods.
The system is designed to be a less invasive, more physiological treatment that helps preserve endothelial function and ensure adequate tissue perfusion, which is essential to maintain individual organ function and prevent multi-organ failure. The oxygenating power of the i-cor is also designed to offer physiological circulatory support, protection, and safety during interventions in the cardiac cath lab, as well as for the management of cardiogenic shock in the intensive care unit (ICU). The i-cor Synchronized Cardiac Assist System is a product of XENIOS (Heilbronn, Germany).
“The i-cor system is the world’s first to synchronize mechanical circulatory support with the patient’s weakened heartbeat. We are able to superimpose or overlay an artificial heartbeat over each weakened heartbeat,” said Georg Matheis, MD, managing director of XENIOS. “This advance not only makes possible new therapy options for patients who are suffering from cardiogenic shock, but also is designed to bridge patients across high-risk interventions in the cardiac cath lab.”
“Patients with cardiogenic shock have a very high mortality rate; in fact, cardiogenic shock as the result of a heart attack is a medical emergency, resulting from an inadequate circulation of blood due to primary failure of the heart ventricles to function effectively,” said Juergen Boehm, MD, managing director of XENIOS. “As this is a type of circulatory shock, there is insufficient perfusion of tissue to meet the demands for oxygen. We are pleased that interventionists will now have a powerful new treatment with which to reduce morbidity and mortality from cardiogenic shock or high-risk interventions.”
Related Links:
XENIOS
The XENIOS i-cor synchronized cardiac assist system uses a miniaturized pump to provide physiological beat-to-beat cardiac assist and concomitant synchronized electrocardiogram (ECG)-triggered pulses that are superimposed over the patient’s weakened heartbeats. The combined myocardial protection and organ perfusion assist the weakened heart to significantly improve coronary blood flow and limit afterload, when compared with conventional methods.
The system is designed to be a less invasive, more physiological treatment that helps preserve endothelial function and ensure adequate tissue perfusion, which is essential to maintain individual organ function and prevent multi-organ failure. The oxygenating power of the i-cor is also designed to offer physiological circulatory support, protection, and safety during interventions in the cardiac cath lab, as well as for the management of cardiogenic shock in the intensive care unit (ICU). The i-cor Synchronized Cardiac Assist System is a product of XENIOS (Heilbronn, Germany).
“The i-cor system is the world’s first to synchronize mechanical circulatory support with the patient’s weakened heartbeat. We are able to superimpose or overlay an artificial heartbeat over each weakened heartbeat,” said Georg Matheis, MD, managing director of XENIOS. “This advance not only makes possible new therapy options for patients who are suffering from cardiogenic shock, but also is designed to bridge patients across high-risk interventions in the cardiac cath lab.”
“Patients with cardiogenic shock have a very high mortality rate; in fact, cardiogenic shock as the result of a heart attack is a medical emergency, resulting from an inadequate circulation of blood due to primary failure of the heart ventricles to function effectively,” said Juergen Boehm, MD, managing director of XENIOS. “As this is a type of circulatory shock, there is insufficient perfusion of tissue to meet the demands for oxygen. We are pleased that interventionists will now have a powerful new treatment with which to reduce morbidity and mortality from cardiogenic shock or high-risk interventions.”
Related Links:
XENIOS
Latest Surgical Techniques News
- Miniaturized Implantable Multi-Sensors Device to Monitor Vessels Health
- Tiny Robots Made Out Of Carbon Could Conduct Colonoscopy, Pelvic Exam or Blood Test
- Miniaturized Ultrasonic Scalpel Enables Faster and Safer Robotic-Assisted Surgery
- AI Assisted Reading Tool for Small Bowel Video Capsule Endoscopy Detects More Lesions
- First-Ever Contact Force Pulsed Field Ablation System to Transform Treatment of Ventricular Arrhythmias
- Caterpillar Robot with Built-In Steering System Crawls Easily Through Loops and Bends
- Tiny Wraparound Electronic Implants to Revolutionize Treatment of Spinal Cord Injuries
- Small, Implantable Cardiac Pump to Help Children Awaiting Heart Transplant
- Gastrointestinal Imaging Capsule a Game-Changer in Esophagus Surveillance and Treatment
- World’s Smallest Laser Probe for Brain Procedures Facilitates Ablation of Full Range of Targets
- Artificial Intelligence Broadens Diagnostic Abilities of Conventional Coronary Angiography
- AI-Powered Surgical Visualization Tool Supports Surgeons' Visual Recognition in Real Time
- Cutting-Edge Robotic Bronchial Endoscopic System Provides Prompt Intervention during Emergencies
- Handheld Device for Fluorescence-Guided Surgery a Game Changer for Removal of High-Grade Glioma Brain Tumors
- Porous Gel Sponge Facilitates Rapid Hemostasis and Wound Healing
- Novel Rigid Endoscope System Enables Deep Tissue Imaging During Surgery